d'Ancona Carlos Arturo Levi, de Lucena Roberto Gonçalves, Querne Fernando Augusto de Oliveira, Martins Mário Henrique Tavares, Denardi Fernandes, Netto Nelson Rodrigues
Division of Urology, Faculdade de Ciências Médicas da Universidade Estadual de Campinas, Sao Paulo, Brazil.
J Urol. 2004 Aug;172(2):498-501; discussion 501. doi: 10.1097/01.ju.0000132239.28989.e1.
We evaluated modified inguinal lymphadenectomy in the treatment of penile carcinoma, analyzing the rate of complications compared to complete inguinal lymphadenectomy, the complications in performing lymphadenectomy and penectomy concomitantly, and the long-term locoregional recurrence rate.
A total of 26 patients with squamous cell carcinoma of the penis were clinically assessed, and underwent penectomy and bilateral modified inguinal lymphadenectomy at the same operative time. Frozen section analysis of lymph nodes was performed and if metastases were detected a complete ipsilateral inguinal dissection was performed.
A total of 52 modified lymphadenectomies were performed. In 10 procedures lymph node metastasis was present. Clinical staging presented false-positive and false-negative rates of 50% and 7.9%, respectively. The complication rate for modified lymphadenectomy was 38.9% and for complete inguinal lymphadenectomy it was 87.5%. Followup ranged from 5 to 112 months and mean followup of recurrence-free cases was 78 months (range 38 to 112). A total of 18 patients underwent bilateral negative modified inguinal lymphadenectomy and 2 of these experienced locoregional recurrence within 2 years after surgery.
Modified inguinal lymphadenectomy causes a lower complication rate than complete inguinal lymphadenectomy. Bilateral modified inguinal lymphadenectomy performed at the same time as penectomy does not increase the complication rate. When frozen section analysis is negative bilaterally, 5.5% of inguinal regions might still harbor occult metastasis. Modified inguinal lymphadenectomy is recommended as a staging procedure in all patients with T2-3 penile carcinoma. A straight followup is required for 2 years since all recurrence was within this period.
我们评估改良腹股沟淋巴结清扫术治疗阴茎癌的效果,分析与根治性腹股沟淋巴结清扫术相比的并发症发生率、同时进行淋巴结清扫术和阴茎切除术的并发症情况以及长期局部区域复发率。
对26例阴茎鳞状细胞癌患者进行临床评估,并在同一手术时间进行阴茎切除术和双侧改良腹股沟淋巴结清扫术。对淋巴结进行冰冻切片分析,若检测到转移,则进行同侧根治性腹股沟清扫术。
共进行了52例改良淋巴结清扫术。其中10例存在淋巴结转移。临床分期的假阳性率和假阴性率分别为50%和7.9%。改良淋巴结清扫术的并发症发生率为38.9%,根治性腹股沟淋巴结清扫术为87.5%。随访时间为5至112个月,无复发病例的平均随访时间为78个月(范围38至112个月)。共有18例患者接受了双侧阴性改良腹股沟淋巴结清扫术,其中2例在术后2年内出现局部区域复发。
改良腹股沟淋巴结清扫术的并发症发生率低于根治性腹股沟淋巴结清扫术。与阴茎切除术同时进行双侧改良腹股沟淋巴结清扫术不会增加并发症发生率。当双侧冰冻切片分析为阴性时,5.5%的腹股沟区域可能仍存在隐匿性转移。对于所有T2-3期阴茎癌患者,建议采用改良腹股沟淋巴结清扫术作为分期手术。由于所有复发均在此期间发生,因此需要进行2年的直接随访。